期刊文献+

十枣汤对腹水型荷瘤小鼠血管内皮生长因子的影响 被引量:6

Vascular Endothelial Growth Factor(VEGF) in Ascites Model Mice's Serum and Ascites with with the Usage of Ten Jujube Decoction
下载PDF
导出
摘要 [目的]观察十枣汤对腹水型荷瘤小鼠血管内皮生长因子(VEGF)的影响。[方法]使用随机平行对照方法,将6~7周龄健康昆明种小鼠90只随机分为正常对照组、荷瘤模型组、5-FU组、十枣汤大、中、小剂量组,每组15只。正常对照组不予处理,其余小鼠局部消毒后,腹腔内注射腹水型H22肝癌瘤细胞株0.2mL/只。次日起5-FU对照组腹腔内注射5-FU 25mL/kg,隔日1次,共5次。十枣汤组小鼠按27g/kg、81g/kg、160g/kg不同剂量等体积十枣汤灌胃,0.4mL/次,1次/d,连续10天。荷瘤模型空白对照组等容积生理盐水灌胃。各组末次给药24h后(腹腔传代第7日),称体重,脱颈椎处死,眼眶取血,抽吸乳白色浓稠腹水。检测血清VEGF、腹水VEGF。[结果]血清VEGF模型组、5-FU组、中药低剂量组、中药中剂量组、中药高剂量组较正常对照组血清VEGF均有不同程度增高(P<0.01);与模型组相比,均有显著性差异(P<0.05);与5-FU组相比,中药组均无显著性差异(P>0.05);其中中药低剂量组与中药高剂量组相比有显著性差异(P<0.05)。腹水VEGF 5-FU组、中药低剂量组、中药中剂量组、中药高剂量组较模型组腹水VEGF均有不同程度降低(P<0.05);与5-FU组相比,各中药低剂量组有显著性差异;中药中、高剂量无显著性差异(P>0.05);中药低剂量与中药中、高剂量均有显著性差异(P<0.05);中药中剂量与中药高剂量相比较无显著性差异(P>0.05)。[结论]十枣汤对腹水型荷瘤小鼠血清VEGF、腹水VEGF有与5-FU类似的抑制作用,并与剂量呈量效关系,这可能是十枣汤治疗恶性腹水,延长生存期、改善生存质量的作用机制。 [ Objective ] To study how the level of vascular endothelial growth factor (VEGF) in ascites model mice's serum and ascites with Ehrlich ascites carcinoma Cell Strain changed with the usage of Ten Ju- jube Decoction. To explore the efficacy and mechanism of Ten Jujube Decoction related with malignant asci- tes. [Method] Randomized, parallel control method will be 6 to 7 weeks of age, healthy Kunming mice 90 were randomly divided into normal control group, tumor - bearing model group, 5 - FU group, Ten, Jujube Decoction large, medium and small dose group, n = 15only. Normal control group not treated, local disinfection of the remaining mice after intraperitoneal injection of ascites H22 hepatoma cell line O. 2mL / only. 5 - FU following the date of the abdominal cavity in the control group injected with 5 - FU, 25mL/kg every other day, a total of five times. 11 KM group mice 27g/kg, 81g/kg, 160g/kg different dose volume Ten, Jujube Decoction gavage 0.4mL / 1 / d for 10 consecutive days. Tumor - bearing model control group of equal vol- ume of normal saline. After the last administration of each group 24 hours ( abdominal pass on behalf of the first 7 days) , weighed, by cervical dislocation were sacrificed, eyes blood, aspiration of milky white thick ascites. Serum levels of VEGF, ascites VEGF. [Results] The serum VEGF model group, 5 - FU group, traditional Chinese medicine low dose group, dose group in the traditional Chinese medicine, Chinese medicine high dose group compared with normal control serum VEGF increased in varying degrees ( P 〈 0.01 ) ; Com- pared with model group, there were significant differences ( P 〈 0.05 ) ; compared with 5 - FU group, the Medicines there was no significant difference ( P 〉 0.05 ) ~ Chinese Medicine low dose group and traditional Chinese medicine high dose group compared to the significant difference ( P 〈 0.05 ). Varying degrees of ascites of VEGF 5 - FU group, traditional Chinese medicine low dose group, dose group in the traditional Chinese medicine, Chinese medicine high dose group compared with model group, ascites VEGF decreased (P 〈 0. 05 ) ; compared with 5 - FU group, the traditional Chinese medicine low dose group a significant difference ; Chinese herbal medicine, high doses without significant significant difference (P 〉 0.05 ) ; Chinese medicine low dose and traditional Chinese medicine, high doses are significant with differences P 〈 0.05 ; Chinese herbal medicine dose and traditional Chinese medicine high dose phase comparison without significant difference (P 〉 0.05 ). [ Conclusion] In high dose group, Ten Jujube Decoction can Significantly reduce the level of vascular endothelial growth factor (VEGF) in ascites model mice's serum and ascites. So, Ten Jujube Decoction can inhibit tumor growth
出处 《实用中医内科杂志》 2012年第5期5-6,10,共3页 Journal of Practical Traditional Chinese Internal Medicine
基金 湖北省教育厅项目(D200616003)
关键词 腹水型荷瘤小鼠血管内皮生长因子 十枣汤 伤寒论 血清VEGF 腹水VEGF 5-FU 腹水型H22肝癌瘤细胞株 量效关系 随机平行对照研究 malignant ascites, Ten Jujube Decoction, vascular endothelial growth factor (VEGF)
  • 相关文献

参考文献8

  • 1Suzuki K, Hayashi N, Miyamoto Y, et al. Expression of vascular permeabilityfaetor/vascular endothelial growth factor in human hepatoce - 1 lular carcinoma [ J ]. Cancer Res, 1996,56 (8) :3004 - 3009.
  • 2Chow NH, Hsu PL, Lin XZ, et al. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma : an immunohistochemical Study [ J ]. Hum Pathol, 1997,28 (6) :698 - 703.
  • 3Hatva E, Bohling T, Jaaskelainen J, et al. Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas [J]. Am J Pathol,1996, 148 (3) :763 -775.
  • 4Cornali E, ZietZ C, Benelli R, et al. Vascular growth factor regulate angiogenesis and vascular permeability in Kaposi' s sarcoma [ J ]. Am J Pathol,1996, 149(6) :1851 - 1869.
  • 5Stracke JO, Hutton M, Stewart M, et al. Biochemical characterization of the catalytic domain of human matrixmetalloproteinase 19. Evidence for a role as a potent basement membrane degradingenzyme [ J ]. J Boil Chem, 2000, 275(20) : 14809 - 14816.
  • 6朱颖蔚,周民,岑岭.恶性肿瘤患者胸水血管内皮生长因子、P53的表达及意义[J].临床荟萃,2005,20(23):1350-1351. 被引量:1
  • 7孙瑜,王良兴,王惠军,李翊卫.VEGF、CD44_(V6)、MMP联合检测对良、恶性胸水的鉴别意义[J].温州医学院学报,2006,36(4):350-353. 被引量:6
  • 8蒋军红,黄建安,郑黎.血管内皮生长因子(VEGF)在恶性胸腔积液中的诊断价值[J].临床医学,2004,24(9):1-2. 被引量:1

二级参考文献18

  • 1Dong-Sheng Cheng, Michael Rodriguez R Elizabeth A et al. Vascular endothlial growth factorin pleural fluid. Chest 1999;166:760~765.
  • 2Thickett D R,Armstrong L,Millar A B. Vascular endothlial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 1999,54:707~710.
  • 3ZEBROWSKI B K, LIU W, RAMIREZ K, et al. Markedly elevated levels of vascular endothelial growth factor in malignant ascites[J]. Ann Surg Oncol, 1999,6 (4): 373-378.
  • 4GROVE C S,LEE Y C. Vascular endothelial growth factor: the key mediator in pleural effusion formation[J]. Curr Opin Pulm Med, 2002,8(4) : 294-301.
  • 5Braunschweig R, Yan E Guilleret I, et al. Detection of malignant effusions: comparison of a telomerase assay and cytologic examination[J]. Diagn Cytopathol, 2001, 24(3): 174-180.
  • 6Motherby H, Nadjari B, Friegel P, et al. Diagnostic accuracy of effusion cytology[J]. Diagn Cytopathol, 1999,20(6): 350-357.
  • 7Zeimet AG, Widschwendter M, Uhl-Steidl M, et al. High serum levels of soluble CD44 variant isoform V5 are associated with favorable clinical outcome in ovarian cancer[J]. Br J Cancer, 1997,76(12): 1646-1651.
  • 8Peterson RM, Yu Q, Stamenkovic I, et al. Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites[J]. Am J Pathol,2000,156(6):2159-2167.
  • 9Weidner N.Introtumor microvessel density as a prognostic factor in cancer[J].Am J Pathol,1995,147(1):9-19.
  • 10Mori A,Arii S,Furutani M,et al. Soluble Flt- 1 gene therapy for peritoneal metastases using HVJ-cationic liposomes[J]. Gene Therapy, 2000,7(7): 1027-1033.

共引文献5

同被引文献109

引证文献6

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部